ER+ breast cancers resistant to prolonged neoadjuvant letrozole exhibit an E2F4 transcriptional program sensitive to CDK4/6 inhibitors

ER+ breast cancers resistant to prolonged neoadjuvant letrozole exhibit an E2F4 transcriptional program sensitive to CDK4/6 inhibitors. Guerrero-Zotano, A.; Stricker, T.; Formisano, L.; Hutchinson, K. E.; Stover, D. G.; Lee, K. M.; Schwarz, L. J.; Giltnane, J. M.; Estrada, M. V.; Jansen, V. M.; Servetto, A.; Gavilá, J.; Pérez-Fidalgo, J. A.; Lluch, A.; Llombart-Cussac, A.; Bayar, M. A.; Michiels, S.; Andre, F.; Arnedos, M.; Guillem, V.; Ruiz-Simon, A.; Arteaga, C. L.. Clin Cancer Res. 2018; 2517-2529: p.2517-2529. doi:10.1158/1078-0432.CCR-17-2904
Article